Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,005 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: hormone therapy Clear all
Completed No phase listed Observational

CTC Immune Checkpoint

NCT02456571
View directory record Official record
Conditions
Prostate Cancer
Interventions
CTC biomarker expression prevalence
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 20, 2026, 7:19 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS

NCT00722800
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
drospirenone and ethinyl estradiol (YAZ), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 20, 2026, 7:19 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer

NCT00598312
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide Acetate for Injectable Suspension
Drug
Lead sponsor
Oakwood Laboratories, LLC
Industry
Eligibility
45 Years and older · Male only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Oakwood Village, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced Oct 20, 2026, 7:19 AM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ribociclib, Endocrine Therapy (ET)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
5,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
73
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 7:19 AM EDT
Not listed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005992
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA prostate cancer vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 20, 2026, 7:19 AM EDT
Completed Phase 4 Interventional Results available

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

NCT01400516
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Teriparatide, calcium citrate, Vitamin D, TNF antagonist
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 20, 2026, 7:19 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

NCT00905021
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Exemestane, Sutent
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 20, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Influence of Male Hormones on Regional Fat Metabolism

NCT01160328
View directory record Official record
Conditions
Obesity
Interventions
Leuprolide, Testosterone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 20, 2026, 7:19 AM EDT
Completed Phase 2 Interventional

Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer

NCT00166543
View directory record Official record
Conditions
Breast Cancer
Interventions
TAS-108
Drug
Lead sponsor
SRI International
Industry
Eligibility
18 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Oct 20, 2026, 7:19 AM EDT
Recruiting No phase listed Observational

Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer

NCT04775355
View directory record Official record
Conditions
Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Biospecimen Collection, Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 7:19 AM EDT
Completed Phase 3 Interventional Results available

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

NCT00390455
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Fulvestrant, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Placebo Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
368
States / cities
Little Rock, Arkansas • Arroyo Grande, California • Burbank, California + 259 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 20, 2026, 7:19 AM EDT
Completed Phase 4 Interventional

Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

NCT02537691
View directory record Official record
Conditions
Asthma
Interventions
FP, LABA, LTRA, LAMA, Theophylline, Oral Corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Birmingham, Alabama • Mission Viejo, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 20, 2026, 7:19 AM EDT
Completed Phase 1 Interventional

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

NCT05759949
View directory record Official record
Conditions
PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
Interventions
RLY-5836, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib
Drug
Lead sponsor
Relay Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Orlando, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 20, 2026, 7:19 AM EDT
Completed No phase listed Observational

Oral Aromatase Inhibitors Modify the Gut Microbiome

NCT05030038
View directory record Official record
Conditions
Breast Cancer
Interventions
Fecal swab collection, Blood samples
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 20, 2026, 7:19 AM EDT
Recruiting Phase 4 Interventional

LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions

NCT05786417
View directory record Official record
Conditions
Angina, Stable Ischemic Heart Disease
Interventions
Clinician Discretion, Beta blocker, Calcium channel blocker
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
65 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
New Haven, Connecticut • Marietta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 20, 2026, 7:19 AM EDT
Terminated Phase 3 Interventional Results available

STRIDE - STimulating Immune Response In aDvanced brEast Cancer

NCT00925548
View directory record Official record
Conditions
Breast Cancer
Interventions
Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
Biological · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 20, 2026, 7:19 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

NCT06084338
View directory record Official record
Conditions
Prostate Cancer
Interventions
stereotactic ablative radiotherapy, Pluvicto, topical testosterone
Radiation · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
4
States / cities
West Los Angeles, California • Hines, Illinois • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 20, 2026, 7:19 AM EDT
Completed Phase 2 Interventional

Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer

NCT03654638
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Dietary Intervention, Questionnaire Administration
Combination Product · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 20, 2026, 7:19 AM EDT
Completed Not applicable Interventional

Treatment for Sleep Disturbance in Orthopaedic Trauma Patients

NCT03779243
View directory record Official record
Conditions
Sleep Disturbance, Trauma
Interventions
Melatonin 5mg and Sleep Education, Placebo
Dietary Supplement · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 20, 2026, 7:19 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358
View directory record Official record
Conditions
Breast Neoplasms
Interventions
pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 20, 2026, 7:19 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

NCT00953576
View directory record Official record
Conditions
Prostate Cancer
Interventions
ketoconazole, hydrocortisone, dutasteride, lapatinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 20, 2026, 7:19 AM EDT
Completed Phase 3 Interventional Results available

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

NCT02906917
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin degludec/insulin aspart, Insulin glargine, Insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 20, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders

NCT02824627
View directory record Official record
Conditions
Mood Disorder, Disruptive Behavior Disorders
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
10 Years to 18 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 20, 2026, 7:19 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer

NCT04298086
View directory record Official record
Conditions
Breast Cancer, Primary Hormone Receptor Positive Breast Cancer
Interventions
Exercise Treatment, Plant-Based Diet, Physical activity, Nutrition counseling, Replication Exercise Test
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 20, 2026, 7:19 AM EDT